$DRTS News

HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16

Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success

Alpha Tau Medical Announces Positive Data In Head And Neck Cancer Treatment Study, Hitting 100% Objective Response Rate Across Nine Evaluable Patients

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Medical Treats First Patient In ADMIRE Study, Clinical Trial Evaluating Intratumoral Alpha DaRT For Immunocompromised Patients With Recurrent Cutaneous Squamous Cell Carcinoma

Alpha Tau Medical: Alpha Particles Are Still Interesting, But Beware The Hype

Alpha Tau Medical’s (DRTS) First International Brain Cancer Use Tests The Breadth Of Its Alpha DaRT Platform

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Medical Announces Success Treatment With Alpha DaRT Of First Glioblastoma Patient In Israel

Alpha Tau Medical: A Lot Of Shots On Goal

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

Alpha Tau Medical Receives FDA Clearance To Proceed With Enrollment Of Final Seven Patients In U.S. REGAIN Trial

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target

Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $17

DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Alpha Tau Medical and Tolmar Form U.S. Prostate Cancer Partnership To Commercialize Alpha DaRT Therapy With Exclusive Rights And Long-Term Revenue Sharing Deal